Mitochondrial DNA damage by bleomycin induces AML cell death

[1]  Q. Yin,et al.  Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone and bleomycin in patients with relapsed/refractory diffuse large B-cell lymphoma , 2014, Leukemia & lymphoma.

[2]  Justin J. Wilson,et al.  Targeting mitochondrial DNA with a platinum-based anticancer agent. , 2013, Chemistry & biology.

[3]  E. Hatzimichael,et al.  Revisiting bleomycin from pathophysiology to safe clinical use. , 2013, Critical reviews in oncology/hematology.

[4]  T. Kasamatsu,et al.  Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102) , 2013, British Journal of Cancer.

[5]  S. Kelley,et al.  Targeted delivery of doxorubicin to mitochondria. , 2013, ACS chemical biology.

[6]  John M. Ashton,et al.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.

[7]  Elsa Alcoba,et al.  Tailoring the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva: Neoadjuvant Chemotherapy Followed by Radical Surgery , 2012, International Journal of Gynecologic Cancer.

[8]  B. Van Houten,et al.  Mitochondrial DNA-depleted A549 cells are resistant to bleomycin. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[9]  T. Ozben,et al.  Synergistic anticancer activity of curcumin and bleomycin: an in vitro study using human malignant testicular germ cells. , 2012, Molecular medicine reports.

[10]  G. Giaever,et al.  Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. , 2011, Cancer cell.

[11]  N. Larsson,et al.  Mitochondrial DNA mutations in disease and aging , 2011, The Journal of cell biology.

[12]  M. Minden,et al.  Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells. , 2011, Chemistry & biology.

[13]  A. Hackshaw,et al.  Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial , 2009, The Lancet. Oncology.

[14]  M. Spitz,et al.  Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. , 2008, Journal of the National Cancer Institute.

[15]  V. Bohr,et al.  DNA repair, mitochondria, and neurodegeneration , 2007, Neuroscience.

[16]  J. Fleck,et al.  Bleomycin lung toxicity: who are the patients with increased risk? , 2005, Pulmonary pharmacology & therapeutics.

[17]  J. Stubbe,et al.  Bleomycins: towards better therapeutics , 2005, Nature Reviews Cancer.

[18]  S. Sleijfer.  Bleomycin-induced pneumonitis. , 2001, Chest.

[19]  C. Maggi,et al.  Apoptotic events in a human ovarian cancer cell line exposed to anthracyclines. , 2001, The Journal of pharmacology and experimental therapeutics.

[20]  B. Van Houten,et al.  Repair of DNA damage in mitochondria. , 1999, Mutation research.

[21]  L. Stivala,et al.  Involvement of proliferating cell nuclear antigen in DNA repair after damage induced by genotoxic agents in human fibroblasts. , 1993, Carcinogenesis.

[22]  M. Smerdon,et al.  Bleomycin-induced DNA damage and repair in human cells permeabilized with lysophosphatidylcholine. , 1990, Cancer research.

[23]  F. Sanger,et al.  Sequence and organization of the human mitochondrial genome , 1981, Nature.

[24]  B. Van Houten,et al.  Quantitative PCR-based measurement of nuclear and mitochondrial DNA damage and repair in mammalian cells. , 2006, Methods in molecular biology.

[25]  C. Muller,et al.  The activity of the DNA-dependent protein kinase (DNA-PK) complex is determinant in the cellular response to nitrogen mustards. , 2000, Biochimie.

[26]  B. Sikic.  Biochemical and cellular determinants of bleomycin cytotoxicity. , 1986, Cancer surveys.